Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Kerry Fisher Mariolina Salio
Kerry Fisher SalioMariolina.jpg


Learning Outcomes

By the end of this module the student will be able to describe:

  1. The evidence base for the immune system being important in anti-tumour immunity
  2. What makes a good tumour antigen
  3. Pros and cons of adoptive T cell therapy, DC vaccination, tumour antigen vaccination
  4. The advantage of using bacteria or viruses to induce anti-tumour immunity
  5. Why checkpoint inhibitors work in only a fraction of patients
  6. How to study the immune response in cancer patients
  7. How to design a cancer vaccine

Indicative Content

This module will give insights into immuno-oncology and cover the molecular basis of tumour immunology as well as emerging and established therapies (checkpoint inhibitors, CAR T cells and adoptive T cell therapy) and how novel biomarkers in this area can be used in stratified health care; the role of microbiota; the complexity of the tumour microenvironment.